kabutan
N225

64,631.78

+0.95%

TOPIX

3,879.62

+0.71%

USDJPY

160.20

+0.01%

Innovacell surges to daily limit after patent registration for incontinence treatment announced

Mon Jun 8, 2026 11:00 am JST Catalyst

Innovacell <504A> shares locked at their daily limit-up ceiling of 710 yen on Monday, rising 100 yen from the previous session. The company, a cell therapy and regenerative medicine venture spun out from the Medical University of Innsbruck in Austria, listed on the Tokyo Stock Exchange Growth Market on February 24. Innovacell maintains a pipeline targeting incontinence treatments, and is currently conducting a joint Japan-Europe Phase 3 clinical trial for its development product ICEF15, which targets fecal urgency incontinence. It is also preparing a Phase 3 trial for ICES13, which targets stress urinary incontinence. Buying interest was fueled by news that a patent titled "Myogenic Progenitor Cells Used in an Optimized Method for the Prevention and Treatment of Anal Incontinence" was registered on Monday, serving as a catalyst for the stock.

Source: MINKABU PRESS

*Translated by generative AI. Click here for the original article.